• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Proquin XR (ciprofloxacin HCl extended-release) Tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- April 2009


The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format.

Summary View


Brand (Generic) Name

Sections Modified

Proquin XR (ciprofloxacin HCl extended-release) Tablets




“new safety information” with the use of Proquin, particularly the increased risks of tendonitis and tendon rupture.

  • What is the most important information I should know about Proquin?
    • Tendon rupture or swelling of the tendon (tendinitis)